RESUMEN
Prevention of respiratory syncytial virus (RSV) disease may ultimately be possible with active immunization, although no vaccine is currently available. Formalin-inactivated RSV vaccine caused serious disease in some recipients re-exposed to RSV, which slowed vaccine development. Current RSV vaccine candidates include RSV fusion protein vaccines, chimeric fusion protein-glycoprotein vaccines, and various live, attenuated RSV vaccines. RSV vaccines may be problematic in very young infants and newborns because of the relatively poor immunogenicity of most vaccine candidates to date. Passive immunization with human polyclonal intravenous immune globulin and humanized monoclonal antibody directed against the conserved fusion protein of RSV prevents severe RSV disease, although not necessarily viral infection. The humanized RSV monoclonal antibody is licensed for use in premature infants and infants with bronchopulmonary dysplasia and is being evaluated in infants with cardiac disease. Another innovative approach to prevent RSV disease in young infants is maternal immunization with a vaccine such as the purified fusion protein vaccine. Such a vaccine could stimulate antibody response to RSV surface glycoproteins and potentially prevent RSV disease in the mother, while maternal antibodies produced could be passively transmitted across the placenta to the infant. A pilot study in postpartum women demonstrated immunogenicity with no significant adverse reactions.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Infecciones por Virus Sincitial Respiratorio/inmunología , Infecciones por Virus Sincitial Respiratorio/prevención & control , Vacunas Virales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Femenino , Humanos , Inmunización Pasiva , Palivizumab , Embarazo , Complicaciones Infecciosas del Embarazo/inmunología , Complicaciones Infecciosas del Embarazo/prevención & control , Complicaciones Infecciosas del Embarazo/virología , Vacunación , Vacunas Atenuadas/uso terapéuticoRESUMEN
Children with suspected respiratory syncytial virus infection were examined prospectively in a randomized evaluation of standard ribavirin aerosol therapy (6 gm/300 ml water for 18 hours daily) compared with high-dose, short-duration ribavirin aerosol therapy (6 gm/100 ml water given for a period of 2 hours three times a day) by means of an oxygen hood (n = 20) or a ventilator (n = 12). Viral shedding was quantitated daily; clinical observations were recorded daily by 2 physicians aware and one unaware of treatment assignments. Study characteristics evaluated at entry were not significantly different in the high-dose and the standard-dose groups. Viral titers and clinical scores decreased similarly in both groups during the study; pulmonary function test results were also similar at discharge in children not receiving mechanical ventilation. Potential complications related to aerosol therapy were noted in three patients (one hood patient who was receiving standard therapy; two patients with an endotracheal tube in place who were receiving high-dose therapy); substantial crystallization was noted in the tubing of the patients undergoing intubation and receiving high-dose therapy. Environmental sampling revealed that ribavirin was nearly undetectable near patients supported by mechanical ventilation who were receiving either form of therapy, and was significantly decreased on a daily basis in patients without an endotracheal tube who were receiving high-dose therapy compared with those receiving standard therapy. The effects of high-dose, short-duration aerosol ribavirin therapy were similar to those of standard-dose therapy in our study patients and resulted in a decreased release of ribavirin into the room of patients receiving therapy by means of an oxygen hood.
Asunto(s)
Infecciones por Virus Sincitial Respiratorio/tratamiento farmacológico , Ribavirina/administración & dosificación , Aerosoles , Microbiología del Aire , Niño , Preescolar , Esquema de Medicación , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Terapia por Inhalación de Oxígeno/instrumentación , Infecciones por Virus Sincitial Respiratorio/terapia , Virus Sincitiales Respiratorios/aislamiento & purificación , Resultado del TratamientoRESUMEN
STUDY OBJECTIVE: To determine the pharmacokinetic parameters of acyclovir disposition in neonates with renal dysfunction. DESIGN: Prospective sequential open enrollment of neonates with presumed herpes group virus infections. SETTING: Neonatal intensive care units in the greater Minneapolis-St. Paul metropolitan area. PATIENTS: Sixteen neonates with gestational ages between 27 and 40 weeks (median 38 weeks) were given acyclovir between days 1 and 56 of life to treat presumed herpes virus infections. Six infants were critically ill with multisystem disease, five infants had hepatic failure and underwent blood exchange transfusion, and five infants had renal failure. A mean of four (range 1 to 19) serum acyclovir concentrations per patient were measured by radioimmunoassay. Pharmacokinetic parameters were calculated from acyclovir concentrations in 46 samples from 16 patients. MEASUREMENTS AND MAIN RESULTS: The pharmacokinetic disposition of acyclovir was described as a two-compartment model. Although the ranges for acyclovir clearance and terminal elimination (t 1/2 beta) were wide, a statistically significant relationship was demonstrated between clearance and beta versus serum creatinine concentration. The average t 1/2 beta for infants with serum creatinine level less than 1 mg/dl (88 mumol/L) was 5.0 hours, and 15.6 hours for those with serum creatinine level greater than 1 mg/dl. CONCLUSIONS: Neonates with hepatic or renal dysfunction or young premature infants accumulate acyclovir when dosed without adjustment for organ dysfunction. Measurement of serum creatinine or creatinine clearance can be useful in the dosing of acyclovir in neonates.
Asunto(s)
Aciclovir/farmacocinética , Herpes Simple/tratamiento farmacológico , Herpes Zóster/tratamiento farmacológico , Aciclovir/administración & dosificación , Aciclovir/sangre , Creatinina/sangre , Herpes Simple/complicaciones , Herpes Zóster/complicaciones , Humanos , Lactante , Recién Nacido , Recien Nacido Prematuro , Enfermedades Renales/complicaciones , Enfermedades Renales/fisiopatología , Hepatopatías/complicaciones , Hepatopatías/fisiopatología , Estudios ProspectivosRESUMEN
Nine children (aged 6 weeks to 7 years) with suspected respiratory syncytial virus infection received aerosal treatment with ribavirin, 60 mg/ml for 2-hour periods three times daily for up to 5 days. Five children received treatment via an endotracheal tube and four via an oxygen hood. Blood samples (3 to 17 per patient) and respiratory secretions (4 to 23 per patient) were assayed for ribavirin with reverse-phase high-performance liquid chromatography. Ribavirin triphosphate in erythrocytes was determined by ion-exchange high-performance liquid chromatography. The mean (+/- SD) peak ribavirin level after the first dose was 1725 +/- 2179 mumol/L in secretions and 3.8 +/- 2.6 mumol/L in plasma. Ribavirin in the secretions was rapidly cleared, with a mean (+/- SD), half-life of 1.9 +/- 0.8 hours. Plasma ribavirin increased with treatments to reach a steady state of 5 to 10 mumol/L. Mean peak ribavirin triphosphate levels were 15- to 300-fold higher than plasma ribavirin levels by the end of therapy. More than 98% reduction of viral load without the emergence of resistant virus was noted on day 3 of therapy. High-dose treatment was compatible with the aerosol equipment routinely used (small-particle aerosol generator, model 2-6000) for ribavirin administration and with ventilators. High-dose, short-duration ribavirin therapy was well tolerated by all patients, permitted easier accessibility for patient care, and may result in less environmental exposure of health care workers.
Asunto(s)
Infecciones del Sistema Respiratorio/tratamiento farmacológico , Infecciones por Respirovirus/tratamiento farmacológico , Ribavirina/administración & dosificación , Ribonucleósidos/administración & dosificación , Administración por Inhalación , Aerosoles , Niño , Preescolar , Cromatografía Líquida de Alta Presión , Esquema de Medicación , Humanos , Lactante , Intubación Intratraqueal , Virus Sincitiales Respiratorios/aislamiento & purificación , Infecciones del Sistema Respiratorio/etiología , Ribavirina/farmacocinética , Ribavirina/uso terapéutico , Factores de TiempoRESUMEN
STUDY OBJECTIVE: To determine whether acyclovir administered orally affects the duration and severity of varicella in otherwise normal children. DESIGN: Randomized, placebo-controlled, double-blind trial. SETTING: Patients' residence and university hospital clinic. PATIENTS: One hundred five children between 5 and 16 years of age with laboratory-confirmed varicella entered the study. Of the 102 who were included in the final analysis, 50 received acyclovir and 52 received placebo. INTERVENTION: Placebo or acyclovir was given orally four times daily, for 5 to 7 days. The acyclovir dose was adjusted as follows: 5 to 7 years of age, 20 mg/kg; 7 to 12 years, 15 mg/kg; and 12 to 16 years, 10 mg/kg. MEASUREMENTS AND MAIN RESULTS: Acyclovir recipients, compared with the placebo group, defervesced sooner (median, 1 day vs 2 days; p = 0.001), experienced onset of cutaneous healing sooner, as reflected by a decrease in number of lesions (median, 3 days vs 2 days; p = 0.002), and had fewer skin lesions (median, 500 vs 336; p = 0.02). Acyclovir did not significantly change the rate of complications of varicella (10% in the acyclovir group vs 13.5% among placebo subjects). Adverse drug effects were not observed. Acyclovir recipients had lower geometric mean serum antibody titers to varicella-zoster virus than their placebo counterparts 4 weeks after the onset of illness, but antibody titers in both groups were similar 1 year later. CONCLUSIONS: These results provide evidence that acyclovir is useful and well tolerated for treatment of varicella in otherwise healthy children.
Asunto(s)
Aciclovir/uso terapéutico , Varicela/tratamiento farmacológico , Aciclovir/administración & dosificación , Adolescente , Varicela/microbiología , Varicela/patología , Niño , Preescolar , Método Doble Ciego , Femenino , Herpesvirus Humano 3/aislamiento & purificación , Humanos , Masculino , Placebos , Prurito/patología , Ensayos Clínicos Controlados Aleatorios como Asunto , Cicatrización de HeridasRESUMEN
A placebo-controlled study of varicella vaccine given either with or 6 weeks after measles-mumps-rubella (MMR) vaccine was undertaken in healthy children (mean age 16 months). A total of 101 varicella-zoster virus antibody-negative children completed the study. Serologic response to MMR vaccine was excellent (nearly 100%) and not significantly affected by the administration of varicella vaccine. Seroconversion in response to varicella vaccine was excellent and was not affected by MMR vaccine. No significant differences in fever or skin rashes between those receiving MMR vaccine with varicella vaccine or MMR vaccine with placebo were noted, but fever and skin rashes were more frequent after the first immunization (MMR with varicella vaccine or MMR vaccine with placebo) compared with the second (varicella vaccine or placebo injection). Symptoms of fatigue, irritability, and upper respiratory tract infections were more common after MMR vaccine was given regardless of whether it was given simultaneously with varicella vaccine or placebo injection.